Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

216,631-216,660 of 319,975

filter-aware
13
The slide uses a stepped process diagram to illustrate dose escalation cohorts.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
14
The slide uses a comparative bar chart approach to justify the human half-life prediction based on NHP data.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
15
Uses icon-based visualization to represent injection frequency.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
16
The slide uses a combination of a pharmacokinetic simulation line chart and a bar chart showing clinical remission rates by exposure quartile.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
17
The slide uses a timeline-like visual to compare dosing schedules at weeks 0, 2, and 6.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
18
The slide uses a comparative table for safety metrics and a bar chart for ADA rates to establish clinical equivalence/safety.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
19
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
20
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
21
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
22
The funnel diagram illustrates the selection criteria: Monomer/Trimer binder -> Picomolar potency -> Extended half-life.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
23
The slide uses two distinct chart types to demonstrate potency (dose-response curve) and diversity (scatter plot of IC50 vs Relative DcR3/DR3 Blocking).Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
24
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Competition1 hit
25
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
26
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
27
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
28
The slide uses a biological process diagram to illustrate the mechanism of action for three distinct therapeutic assets.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
29
The slide uses a stacked bar chart to visualize the additive clinical remission rates, noting a 22% delta between the individual components and the combination.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
30
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
31
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
32
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
33
The slide includes a section for Management team and Board of Directors with headshots and titles, plus a logo grid at the bottom.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Team1 hit
34
The slide uses a timeline-like structure to map clinical catalysts against expected timeframes.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
35
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
36
The slide details a corporate M&A event and subsequent private placement financing.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
37
Includes a footnote regarding a 1-for-25 reverse stock split effective September 8, 2023.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
01
Slide 1
The logo features negative space silhouettes of a person and a dog within the letters.AKT Pictures | Other Presentation Deck | 17 slides · akt-pictures
Deck Investor relations Beat · What Is1 hit
02
The visual uses a silhouette of a man with a dog's shadow, reinforcing the premise.AKT Pictures | Other Presentation Deck | 17 slides · akt-pictures
Deck Investor relations Beat · What Is1 hit
03
The slide features a personal narrative and a photo of the director on set.AKT Pictures | Other Presentation Deck | 17 slides · akt-pictures
Deck Investor relations Beat · Ordinary WorldLoop · Golden Circle1 hit
04
The slide uses a movie still (likely from 'Clueless') to illustrate the narrative.AKT Pictures | Other Presentation Deck | 17 slides · akt-pictures
Deck Investor relations Beat · Ordinary WorldLoop · Golden Circle1 hit
05
The slide uses a split-image layout to define the film's visual world-building.AKT Pictures | Other Presentation Deck | 17 slides · akt-pictures
Deck Investor relations Beat · Ordinary WorldLoop · Golden Circle1 hit